GPNMB and cancer: Therapeutic suppression of Gpnmb is currently in phase 2 clinical trials for several types of cancer (ClinicalTrials.gov Identifier: NCT01997333, NCT01156753, NCT02713828, NCT02487979, NCT02302339, NCT02280785, NCT00921570, NCT02363283).